Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy

Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy

Nicola Tarantino,1 Francesco Santoro,1,2 Luisa De Gennaro,3 Michele Correale,1 Francesca Guastafierro,1 Antonio Gaglione,1 Matteo Di Biase,1 Natale Daniele Brunetti1 1University of Foggia, Foggia, Italy; 2Asklepios Klinik – St Georg, Hamburg, Germany; 3Ospedale San Paolo, Bari, It...

Full description

Bibliographic Details
Main Authors:	Tarantino N, Santoro F, De Gennaro L, Correale M, Guastafierro F, Gaglione A, Di Biase M, Brunetti ND
Format:	Article
Language:	English
Published:	Dove Medical Press 2017-02-01
Series:	Vascular Health and Risk Management
Subjects:	Fibrates Simvastatin Fixed Dose Combination Combined Dyslipidemia Review.
Online Access:	https://www.dovepress.com/fenofibratesimvastatin-fixed-dose-combination-in-the-treatment-of-mixe-peer-reviewed-article-VHRM

Similar Items

Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
by: Farnier Michel, et al.
Published: (2011-11-01)

Assessment of Adding Fenofibrate to Simvastatin on Exercise Test Findings in Patients with Dyslipidemia and Coronary Artery Disease
by: Reza Karbasi Afshar, et al.
Published: (2013-12-01)

Effects of simvastatin with or without fenofibrate on echocardiographic findings of patients with coronary artery disease and dyslipidemia: a brief report
by: Karbasi-Afshar R, et al.
Published: (2012-09-01)

Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders
by: Agata Górniak, et al.
Published: (2023-02-01)

Fibrane the reduced derivative of fenofibrate
by: Amanda E. Kotheimer, et al.
Published: (2020-01-01)

Potential of combination therapy in patients with hypertension and dyslipidemia
by: T. V. Gorokhova, et al.
Published: (2022-08-01)

Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy Volunteers
by: Yoon DY, et al.
Published: (2020-02-01)

Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy
by: Mariël F. van Stee, et al.
Published: (2018-06-01)

PLATELET HEMOSTASIS DYNAMICS IN SIMVASTATINTREATED PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA
by: I. N. Medvedev, et al.
Published: (2010-02-01)

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
by: Tenenbaum Alexander, et al.
Published: (2012-10-01)

Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men
by: Thomas Sudhop, et al.
Published: (2009-10-01)

Study of the Functional State of the Proximal Renal Tubules in Patients with Asymptomatic Chronic Heart Failure in Dyslipidemia and its Correction with Simvastatin Treatment
by: V. Yu. Kopylov
Published: (2020-12-01)

The Combination Effect of Simvastatin and Virgin Coconut Oil on Total Cholesterol Levels in Dislipidemic Male Albino Rats (Rattus norvegicus)
by: Lutfi Dewanda Nugroho, et al.
Published: (2021-08-01)

Influence of anti-hyperlipidemic activity by co-administration of polyamines and rutin with simvastatin
by: Rajesh R Patil, et al.
Published: (2023-01-01)

Preformulation Studies of Ezetimibe-Simvastatin Solid Dispersions in the Development of Fixed-Dose Combinations
by: Agata Górniak, et al.
Published: (2022-04-01)

Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study
by: Lin Zhu, et al.
Published: (2020-03-01)

VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate
by: Michel Farnier, et al.
Published: (2008-12-01)

Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs
by: Donatella Zodda, et al.
Published: (2018-01-01)

PLEIOTROPIC EFFECTS OF SIMVASTATIN AND FENOFIBRATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: A COMPARATIVE STUDY
by: I. V. Shirinsky, et al.
Published: (2019-01-01)

STATE CONTROL OF THE VASCULAR WALL TO ANTIAGGREGATIVE BY NEUTROPHILS IN PATIENTS ARTERIAL HYPERTENSION WITH DYSLIPIDEMIA PATIENTS TREATED WITH SIMVASTATIN
by: I. N. Medvedev, et al.
Published: (2013-03-01)

Inhibitory effect of the combination therapy of simvastatin and pinocembrin on atherosclerosis in apoE-deficient mice
by: Sang Hui, et al.
Published: (2012-12-01)

Soy milk versus simvastatin for preventing atherosclerosis and left ventricle remodeling in LDL receptor knockout mice
by: L. Santos, et al.

The place of fixed antihypertensive drugs in modern therapy of arterial hypertension
by: Tatiana V. Pinchuk, et al.
Published: (2021-02-01)

THE EFFECTS OF SIMVASTATIN, ROSUVASTATIN, AND FENOFIBRATE ON THE BODY WEIGHT AND LIPID PROFILES OF FEMALE RATS TREATED WITH ORAL CONTRACEPTIVES AND A HIGH-FAT DIET
by: Dwi Anggara Putri, et al.
Published: (2022-09-01)

Co-Administration of Simvastatin Does Not Potentiate the Benefit of Gene Therapy in the mdx Mouse Model for Duchenne Muscular Dystrophy
by: Nathalie Bourg, et al.
Published: (2022-02-01)

LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia
by: Ariel Brautbar, et al.
Published: (2012-03-01)

Brown adipose tissue activity is modulated in olanzapine-treated young rats by simvastatin
by: Xuemei Liu, et al.
Published: (2020-06-01)

Merging Experimental Design and Nanotechnology for the Development of Optimized Simvastatin Spanlastics: A Promising Combined Strategy for Augmenting the Suppression of Various Human Cancer Cells
by: Shaimaa M. Badr-Eldin, et al.
Published: (2022-05-01)

Efficacy and safety of fixed-combination bimatoprost/timolol ophthalmic solution
by: Moon SB, et al.
Published: (2017-06-01)

Fenofibrate and Crataegus oxyacantha is an effectual combo for mixed dyslipidemia
by: Huda A Rasheed, et al.
Published: (2020-01-01)

Dyslipidemia in HIV-infected individuals
by: Eduardo Sprinz, et al.

Limb-girdle muscular dystrophy type 2B causes HDL-C abnormalities in patients and statin-resistant muscle wasting in dysferlin-deficient mice
by: Zoe White, et al.
Published: (2022-11-01)

Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation)
by: V. V. Kashtalap
Published: (2022-12-01)

IMPLICATION OF THE FIXED COMBINATIONS IN THE HYPERTENSION TREATMENT
by: Z. D. Kobalava, et al.
Published: (2016-01-01)

Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
by: Tenenbaum Alexander, et al.
Published: (2004-12-01)

Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis
by: Paweł Kawalec, et al.
Published: (2018-08-01)

Frequency of Use of Fixed-Combination Eye Drops by Patients with Glaucoma at Multiple Private Practices in Japan
by: Inoue K, et al.
Published: (2022-03-01)

MICRORHEOLOGY OF ERYTHROCYTES IN ARTERIAL HYPERTENSION AND DYSLIPIDEMIA WITH A COMPLEX HYPOLIPIDEMIC TREATMENT
by: I. N. Medvedev
Published: (2017-05-01)

TREATMENT OF ARTERIAL HYPERTENSION AND DYSLIPIDEMIA IN REAL CLINICAL PRACTICE. THE SYNERGY STUDY. Part 2
by: O. M. Drapkina, et al.
Published: (2017-07-01)

Opposite metabolic response to fenofibrate treatment in pregnant and virgin rats
by: Ana Soria, et al.
Published: (2002-01-01)